Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
long-acting beta2-adrenergic agonist |
| gptkbp:approvalYear |
2009
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
R03AC18
|
| gptkbp:brand |
Arcapta Neohaler
Onbrez Breezhaler |
| gptkbp:CASNumber |
312753-06-3
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
40-56 hours
|
| gptkbp:hasMolecularFormula |
C24H28F3N3O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
indacaterol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta2-adrenergic receptor agonist
|
| gptkbp:partOf |
combination drug Enerzair Breezhaler
combination drug Ultibro Breezhaler |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103837
11242947 DB05039 |
| gptkbp:routeOfAdministration |
inhalation
|
| gptkbp:sideEffect |
headache
cough nasopharyngitis muscle spasm |
| gptkbp:UNII |
8LJ08WK8A3
|
| gptkbp:usedFor |
chronic obstructive pulmonary disease
|
| gptkbp:bfsParent |
gptkb:Atectura
gptkb:Enerzair |
| gptkbp:bfsLayer |
6
|